Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial

​Senti Biosciences has completed enrolment of patients in its Phase I clinical trial assessing SENTI-202 in adults with relapsed or refractory acute myeloid leukaemia (R/R AML).

The post Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
Merck and Calla Lily partner to advance Callavid platform

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us